Orlistat.
Orlistat (tetrahydrolipstatin) is an inhibitor of pancreatic and other lipases. As a pancreatic lipase inhibitor, it acts in the gastrointestinal lumen and is indicated for use in obesity. Serum total cholesterol and low density lipoprotein-cholesterol levels were reduced in obese, but otherwise healthy, patients during < or = 2 years' orlistat treatment; serum triglyceride and high density and very low density lipoprotein-cholesterol levels were unchanged in trials of < or = 12 weeks. Obese patients who were maintained on a hypocaloric diet and who received orlistat 360 mg/day for 12 weeks lost a significantly greater percentage of bodyweight than placebo recipients (5 vs 3.5%). In 2-year studies, weight loss was significantly greater in orlistat than in placebo recipients by the end of year 1; weight was further reduced or maintained in the second year, when a eucaloric diet was allowed, in orlistat but not placebo recipients. A greater proportion of orlistat than placebo recipients lost > 5% or > 10% of their initial bodyweight in 1- and 2-year studies.
McNeely
W
W
Adis International Limited, Auckland, New Zealand. demail@adis.co.nz
Benfield
P
P
D004361:Drug Tolerance; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D007783:Lactones / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D009765:Obesity / Q000188:drug therapy; D000077403:Orlistat
D007783:Lactones; D000077403:Orlistat